Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
XLIFE SCIENCES AG |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 40.2 CHF | +0.50% | +4.96% | +35.35% | |
| Oct. 18 | Xlife Sciences to Sell Portfolio Company to 4D Lifetec | MT |
| Oct. 18 | Xlife Sciences AG acquired 20% stake in 4D Lifetec AG for CHF 23.3 million. | CI |
| Sales 2023 * | 800K 914K | Sales 2024 * | 800K 914K | Capitalization | 225M 257M |
|---|---|---|---|---|---|
| Net income 2023 * | -4M -4.57M | Net income 2024 * | -4M -4.57M | EV / Sales 2023 * | 361x |
| Net Debt 2023 * | 63.9M 73.04M | Net Debt 2024 * | 65M 74.3M | EV / Sales 2024 * | 362x |
| P/E ratio 2023 * | -55,8x | P/E ratio 2024 * | -60,9x | Employees | 13 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 48.76% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.50% | ||
| 1 week | +3.61% | ||
| Current month | +2.81% | ||
| 1 month | +5.79% | ||
| 3 months | +3.08% | ||
| 6 months | +1.01% | ||
| Current year | +35.35% |
1 week
37.80
41.50
1 month
37.1041.50
Current year
28.6041.90
1 year
27.0041.90
3 years
23.3052.00
5 years
23.3052.00
10 years
23.3052.00
| Managers | Title | Age | Since |
|---|---|---|---|
Oliver Baumann
CEO | Chief Executive Officer | - | 2019 |
Carl von Halem
DFI | Director of Finance/CFO | - | 2021 |
Simone Bonito
ADM | Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Christian Faber
CMP | Compliance Officer | - | 2019 |
Mark Müller
BRD | Director/Board Member | - | 2018 |
Oliver Baumann
CEO | Chief Executive Officer | - | 2019 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 2,471 M€ | +1.16% | - | |
| 0.01% | 920 M€ | +1.24% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-05 | 40.2 | +0.50% | 344 |
| 23-12-04 | 40 | -3.38% | 2,024 |
| 23-12-01 | 41.4 | +5.88% | 6,198 |
| 23-11-30 | 39.1 | +2.89% | 2,315 |
| 23-11-29 | 38 | -0.78% | 2,835 |
Delayed Quote Swiss Exchange, December 05, 2023 at 11:30 am EST
More quotes
Xlife Sciences AG is a Switzerland-based biotechnology company. The Company focuses on investing in technologies in the life science industry. It supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The Company offers its investors direct access to the further development of technologies at a very early stage. The Company cooperates with industrial partners and universities.
Calendar
2024-04-22
- Q4 2023 Earnings Release
Trading Rating :
Investor Rating :
ESG Refinitiv :
-
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
40.2CHF
Average target price
68CHF
Spread / Average Target
+69.15%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +35.35% | 256 M $ | |
| +67.95% | 40 210 M $ | |
| +4.60% | 39 469 M $ | |
| -56.42% | 30 453 M $ | |
| -26.33% | 28 080 M $ | |
| +38.74% | 21 949 M $ | |
| -28.31% | 21 694 M $ | |
| +1.31% | 17 245 M $ | |
| -13.59% | 11 276 M $ | |
| -22.32% | 10 327 M $ |
